Laboratory%20Scientist_edited.jpg
_Q5A6564.jpg
Microscope
Pipetting Samples
Embryonic Stem Cells
Male Scientist
Chemistry Class
Science Student
Plant Biologist

IN THE PRESS

  

 

FZ002 R&D IS PUBLISHED IN TOP JOURNAL

10/28/2020

Research on FZata's leading drug candidate, FZ002, was published in Science Translational Medicine (2020 Oct 28;12(567)).
This break through study was reported by many journals, including Science magazine (https://www.sciencemag.org/news/2020/10/antibody-producing-yeast-vanquishes-deadly-gut-infection-mice), Medical Press (https://medicalxpress.com/news/2020-10-yeast-common-bacterial-intestinal-infection.html), BiotechScope (https://biotechscope.com/antibody-secreting-yeast-immunotherapy-to-treat-deadly-gut-infection/) etc.

FullSizeRender 4.jpg






FZATA WINS NIH SBIR FAST-TRACK GRANT

07/20/2020

FZata wins NIH SBIR Fast-track grant to support the development of FZ002.

FullSizeRender 30.jpg






FZATA IS SPOTLIGHTED BY EAGB

March 1, 2020

EAGB selected FZata as their Industry Spotlight: Life Science company. 
(https://www.greaterbaltimore.org/news/blog/thriving-against-odds-life-sciences-industry)

IMG_6419.JPG





FZATA, INC. WINS 3RD SBIR FUND

01/20/2018

FZata is awarded an SBIR grant to support the development of a novel companion diagnostic assay for C. diff infection

FullSizeRender 26.jpg





FZATA WINS 2ND SBIR FUND

01/15/2018

FZata receives an SBIR Phase I grant to support the development of a novel immunotherapy against comorbidity of C. diff infection and Inflammatory Bowel Disease

FullSizeRender%208_edited.jpg






FZATA WINS  NIH R01 GRANT

March 1, 2017

FZata is awarded an NIH R01 grant to support the development of a novel multi- specific antibody against C. diff infection.

FullSizeRender 11.jpg





FZATA IS HONORED "2017 MARYLAND INCUBATOR COMPANY OF THE YEAR: BEST LIFE SCIENCE COMPANY"

06/15/2017

trophy.jpeg





FZATA, INC. WINS ITS FIRST SBIR GRANT

01/01/2017

FZata is awarded a SBIR Phase I grant from NIAID to support the study of a novel oral immuo-therapy against C. diff infection.

​As NIH grant awardee, FZata will strictly follow the NIH policy on Financial Conflict of Interest. 

Screen%20Shot%202021-04-08%20at%2010.43_edited.jpg